Posted by Michael Wonder on 27 Oct 2020
Kala Pharmaceuticals announces FDA approval of Eysuvis for the short-term treatment of the signs and symptoms of dry eye disease
27 October 2020 - First approved prescription therapy specifically for short-term treatment of dry eye disease.
Kala Pharmaceuticals today announced that the U.S. FDA has approved Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
The FDA granted approval to Eysuvis based on results from four clinical trials, including three Phase 3 trials and one Phase 2 trial, that demonstrated significant improvements in both the signs and symptoms of dry eye disease.
